Compare · CTIC vs LLY
CTIC vs LLY
Side-by-side comparison of CTI BioPharma Corp. (DE) (CTIC) and Eli Lilly and Company (LLY): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CTIC and LLY operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- LLY is the larger of the two at $234.46B, about 1224.7x CTIC ($191.5M).
- LLY has hit the wire 10 times in the past 4 weeks while CTIC has been quiet.
- LLY has more recent analyst coverage (25 ratings vs 7 for CTIC).
- Company
- CTI BioPharma Corp. (DE)
- Eli Lilly and Company
- Price
- $9.09-0.05%
- $884.02-3.63%
- Market cap
- $191.5M
- $234.46B
- 1M return
- -
- -3.48%
- 1Y return
- -
- +0.77%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 1997
- News (4w)
- 0
- 10
- Recent ratings
- 7
- 25
CTI BioPharma Corp. (DE)
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It develops pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase III clinical trials for the treatment of adult patients with myelofibrosis. It has license and collaboration agreement with Teva Pharmaceutical Industries Ltd.; S*BIO Pte Ltd.; and Vernalis (R&D) Limited. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was founded in 1991 and is headquartered in Seattle, Washington.
Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceuticals worldwide. It offers Baqsimi for severe hypoglycemia; Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500, and Lyumjev for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company also provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+ and HER2- metastatic breast cancer. In addition, it offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Further, the company Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; Reyvow for migraine; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Additionally, it Bamlanivimab and etesevimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. Eli Lilly and Company has collaborations with Incyte Corporation; Pfizer Inc.; AC Immune SA; Centrexion Therapeutics Corporation; ImmuNext, Inc.; Avidity Biosciences, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; and MiNA Therapeutics Limited. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Latest CTIC
- SEC Form 15-12G filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
- SEC Form EFFECT filed by CTI BioPharma Corp. (DE)
Latest LLY
- The Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation Trial
- SEC Form 4 filed by Sulzberger Gabrielle
- SEC Form 4 filed by Luciano Juan R
- SEC Form 4 filed by Fyrwald J Erik
- SEC Form 4 filed by Alvarez Ralph
- Lilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapies
- Lilly confirms date and conference call for first-quarter 2026 financial results announcement
- ACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic health
- Lilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLL
- Foundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.